Back to Journals » Drug Design, Development and Therapy » Volume 11

Ten years of biosimilar recombinant human growth hormone in Europe

Authors Saenger P

Received 15 December 2016

Accepted for publication 3 February 2017

Published 16 May 2017 Volume 2017:11 Pages 1505—1507

DOI https://doi.org/10.2147/DDDT.S130317

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Rasika Samarasinghe

Peer reviewer comments 4

Editor who approved publication: Dr Anastasios Lymperopoulos

Paul Saenger

Division of Pediatric Endocrinology, Department of Pediatrics, Winthrop University Hospital, Mineola, NY, USA

Abstract:
Recombinant human growth hormone (rhGH) has been in clinical use for more than 30 years. With the expiration of patent exclusivity for the first wave of rhGH products and other biopharmaceuticals, the opportunity emerged for the development of biosimilar medicines. A biosimilar is defined by the European Medicines Agency (EMA) as a biological medicine that is similar to another biological medicine that has already been authorized for use. The EMA led the way (well ahead of the Food and Drug Administration in the US) in developing the biosimilar concept, and the type of science-based regulatory framework required to ensure high-quality, safe, and effective biosimilar medicines; the provisions for approval of biosimilars have been in place in Europe since 2005. Under these provisions, Omnitrope® was approved by the EMA in 2006 as the world’s first biosimilar medicine; 2016 therefore marks the 10th anniversary of its approval in Europe. A substantial data set, based on clinical development studies and 10 years of postapproval use, has now accumulated for biosimilar rhGH; this data set shows that the product is an effective treatment option for children who require rhGH treatment, and has a safety profile that is consistent with the rhGH class. The decade since the EMA approved biosimilar rhGH has seen the successful approval and clinical use of 20 biosimilar medicines, confirming the integrity of the scientific basis for the biosimilar concept, as well as the quality of regulatory decision-making.

Keywords:
recombinant human growth hormone, Omnitrope®, biosimilar

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways

Schiestl M, Zabransky M, Sörgel F

Drug Design, Development and Therapy 2017, 11:1509-1515

Published Date: 16 May 2017

Ten years of clinical experience with biosimilar human growth hormone: a review of safety data

Borrás Pérez MV, Kriström B, Romer T, Walczak M, Höbel N, Zabransky M

Drug Design, Development and Therapy 2017, 11:1497-1503

Published Date: 16 May 2017

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M

Drug Design, Development and Therapy 2017, 11:1489-1495

Published Date: 16 May 2017